Science Corp Raises $400M Series D to Bring Its Retinal Implant to the US
Science Corporation, the brain-computer interface company founded by Neuralink co-founder Max Hodak, raised a $400M Series D at a $3.5B valuation, according to a source who spoke to TechCrunch. No lead was named. Backers include Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech. TechCrunch: https://techcrunch.com/2026/11/17/science-corporations-brain-tech-is-worth-3-5-billion-after-new-funding/
The product that matters is PRIMA, a tiny wireless chip implanted under the retina for people who lost central vision to dry age-related macular degeneration, the most common cause of blindness in older adults. A camera in a pair of glasses projects the scene onto the chip, and the chip stimulates the surviving retinal cells. PRIMA is already approved in Europe. The new money funds the push for US access through the FDA's Humanitarian Device Exemption, plus a trial in Stargardt disease, an inherited form of macular degeneration.
This is the contrast with most of the BCI field. Many competitors are still selling a future where you control a computer with your thoughts. Science is selling a device that is already approved somewhere and restores something specific. That makes the valuation easier to defend, because it rests on regulators and patients, not just demos.
The broader read: the money going into the human-machine interface layer keeps growing. Agents make the software side of being 100X more capable cheap. The bandwidth between a person and a machine is still a hardware problem, and Science is one of the few companies with an approved product in it.
← Back to all articles
The product that matters is PRIMA, a tiny wireless chip implanted under the retina for people who lost central vision to dry age-related macular degeneration, the most common cause of blindness in older adults. A camera in a pair of glasses projects the scene onto the chip, and the chip stimulates the surviving retinal cells. PRIMA is already approved in Europe. The new money funds the push for US access through the FDA's Humanitarian Device Exemption, plus a trial in Stargardt disease, an inherited form of macular degeneration.
This is the contrast with most of the BCI field. Many competitors are still selling a future where you control a computer with your thoughts. Science is selling a device that is already approved somewhere and restores something specific. That makes the valuation easier to defend, because it rests on regulators and patients, not just demos.
The broader read: the money going into the human-machine interface layer keeps growing. Agents make the software side of being 100X more capable cheap. The bandwidth between a person and a machine is still a hardware problem, and Science is one of the few companies with an approved product in it.
Comments